DOCSLIB.ORG

Cystic Fibrosis Center NEWS SUMMER 2003

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cystic Fibrosis Center NEWS SUMMER 2003 Cystic Fibrosis Center NEWS SUMMER 2003 Sinusitis and Cystic Fibrosis Introduction Respiratory disease in cystic fibrosis (CF) is usually associated with the lungs. However, acute and chronic sinusitis are common complications that can cause significant symptoms that sometimes adversely impact the lungs. Sinusitis is defined as inflammation of the nose and sinuses. Most persons with CF develop sinus symptoms, with onset typically between the ages of 5 and 14. Severity of symptoms and disease varies widely. Treatments include oral, systemic and inhaled medications as well as surgical and medical interventions. In this issue, we will discuss CF-related sinus symptoms, diagnoses and some treatment options that may minimize the discomfort caused by sinusitis. The lungs, nose and sinuses comprise the respiratory tract, and all can be impacted by CF genetic mutations. Anatomically, the lungs comprise the “lower respiratory tract” while the nose and sinuses comprise the “upper respiratory tract.” By evaluating the respiratory tract as one continuous structure, it is easier to understand the causes and treatment of sinus symptoms and disease in persons with CF. Continued on Next Page INSIDE FREQUENTLY ASKED QUESTIONS PAGE 5 LPCH EDUCATION DAY HIGHLIGHTS PAGE 6 PHASE IIB GENE THERAPY TO BEGIN IN JUNE PAGE 7 Devon Wakefield has CF sinusitis and is a dedicated and enthusiastic soccer player. He receives monthly sinus flushes at LPCH. Sinusitis and Cystic Fibrosis The Sinuses in Cystic Fibrosis The sinuses consist of 4 pairs of air filled spaces: the ethmoid, Ethmoid sinuses maxillary, sphenoid and frontal sinuses, located behind the nose, cheeks and eyes. The sinuses warm and humidify the air you Sphenoid sinus breathe. They also filter particles in the air, such as bacteria, Frontal sinus spores and dust. The sinuses, like the lungs, are lined with epithelia cells that contain the defective CFTR that contributes to the inflammation and infection that causes CF complications. Most people with CF suffer from pansinusitis, inflammation and infection of all the sinuses. Maxillary sinus The incidence of sinusitis in CF is not known, but the great majority develop sinus symptoms. Symptoms include: The incidence of “hay fever” or allergic rhinitis is the same I nasal obstruction as the general population. There is no known association of I chronic congestion or discharge allergies causing nasal polyps or the development of asthma or I headaches more serious lung disease. However, since about 20% of persons with CF also have allergies, it is important to pay I post-nasal drip with morning cough attention to known allergies or seasonal worsening of sinus I cough that is aggravated by lying down symptoms so that they can be treated effectively. I severe bad breath Diagnosis I constant need to “clear one’s throat” Diagnosis of CF-related sinusitis is based on symptoms. Adolescents and adults are more likely than children to Imaging studies may help determine the extent of disease. report sinus-related headaches that often don’t respond to Sinus endoscopy, placement of a small camera into the typical headache remedies. Acute sinusitis is the term used maxillary and sometimes ethmoid sinuses for direct viewing, when symptoms become severe. Many persons with CF have is often used by an otolaryngologist (ear, nose and throat chronic, or recurring, sinusitis. specialist) to visualize sinus polyps and obstructions. Nasal and sinus polyps, benign masses of tissue, occur in as Treatment many as 48% of persons with CF and increase in frequency Treatment includes antibiotics, nasal steroids, clearance with age. Polyps can grow over time, and often obstruct with saline or antibiotic flushes, antihistamines and drainage of the nose and sinuses. decongestants and surgical interventions. Although there is no ‘best’ treatment for CF sinus disease, most people will CF sinusitis is distinctive in imaging studies. Improper benefit from a combination of therapies. Modalities are the formation of the frontal sinuses, possibly a result of sinus same as those used for non-CF patients, although dosing and obstruction early in life, is common and can be seen on x-rays. choice of drugs may be different, depending on the specific In CT and MRI scans, more than 75% opacification pathogens found in a culture. (cloudiness) of the maxillary and ethmoid sinuses is a hallmark of CF. Abnormal paranasal sinuses also are common. Like the lungs, the sinuses benefit from “airway clearance.” This includes anything to help remove mucus, such as nose CF-related sinus infections generally are distinct from blowing, saline flushes, saline nasal sprays to moisturize non-CF bacterial sinus infections. Just as in CF lung infections, mucus so it can be “blown out” more easily and the most common sinusitis bacteria are Staphylococcus aureus; ENT-assisted interventions that remove mucus. More Haemophilus influenza; Pseudomonas aeruginosa; Burkholderia aggressive interventions are often recommended for people cepacia; Achromobacter xylosoxidans and Stenotrophomonas with frequent pulmonary exacerbations. maltophilia. People with CF can have high bacterial loads in their sinuses without experiencing symptoms. Non-bacterial Antibiotic treatment for CF sinusitis is similar to that for infectious agents are also found in CF sinusitis. Aspergillus lung exacerbations. Choice of antibiotic is based on the molds colonize up to 40% of sinuses in adults with CF, although specific pathogens and their drug resistances. You should they often do not cause symptoms. Persons with CF are not consult your CF physician before an antibiotic course is more susceptible to common viral upper respiratory infections initiated for sinusitis to ensure the drugs, duration and dosing (the “common cold”). are appropriate. Combination antibiotic therapies are often 2 Lucile Packard Children’s Hospital recommended and dosing can be significantly different than treatment of non-CF sinusitis. Nasal swabs and transantral aspirations for cultures are used, as well as sputum samples, since typically sinuses are infected with the same organisms as the lungs. Laboratories not associated with a CF Center often are not equipped to identify many CF pathogens and drug sensitivity levels that are important to optimum treatment. Treatment courses are usually 3–6 weeks due to the poor penetration of drugs into the sinuses, but there is no ideal length of therapy. Antibiotics can be delivered systemically, via mouth or vein, or locally by inhalation or direct injection into the maxillary sinuses, a process referred to as antibiotic flushing. Systemic antibiotics are the standard of care, and sinus and pulmonary exacerbations are usually treated simultaneously. A recent study of non-CF patients using antibiotics nebulized directly into the sinuses found decreased nasal bacterial counts and inflammation. For users of inhaled TOBI™, sinus penetration of the drug occurs. Nebulizers adapted for inhalation through the nose coupled with an array of antibiotics are now available, and are reported to help some people with CF. Flushing of the maxillary sinuses through catheters placed directly into the sinus is possible in people who undergo surgical antrostomies to enlarge the sinus openings. In two studies involving lung transplant patients, flushing with tobramycin through antrostomies resulted in absence or delay of contamination of the newly transplanted lungs with Pseudomonas. Another study of CF patients with chronic sinusitis showed that those who had monthly flushes with tobramycin had fewer surgeries over a two-year period of time. What remains unclear is how this treatment compares to other forms of “airway clearance” for the upper respiratory tract and the influence of monthly checks on the sinuses. Some patients have monthly appointments in the ENT clinic for flushes, whereas others do the flushes at home. Some patients report relief of sinus symptoms by flushing with saline. Clearing mucus, infectious organisms and hydrating thick secretions may provide symptomatic improvement. Products include saline-filled squeeze atomizers, some of which contain the moisturizing agent glycerol. More economically, patients can flush with a homemade buffered saline solution. (Recipe: Add 1 teaspoon of salt and one pinch of baking soda to a pint of warm water.) The nostrils can be flushed with the saline using a bulb, catheter-tipped syringe or a specially designed nasal irrigation cup available from allergy supply sources. Anna Messner, MD, administers an antibiotic flush procedure on Devon Wakefield. Continued on Next Page www.lpch.org 3 Sinusitis and Cystic Fibrosis Continued from Page 3 Sinus Care at Stanford and LPCH Nasal steroids help some people with CF-related sinusitis. Acute sinusitis in CF patients can be problematic, even after Regular use of nasal steroids may diminish the size and number surgeries, due to chronic infections, sinus pressure, pain of nasal polyps, and their use after polypectomy (removal of and drainage. The Stanford Sinus Center is a unique clinic polyps) may decrease the rate at which polyps re-form. founded by the ENT physicians at Stanford. These doctors use The effectiveness of antihistamines and decongestants in CF several newer tools to help with the diagnosis and treatment is inconclusive. For some, they are too dehydrating. For others, of sinus infections. Sinus Center physicians who routinely especially those with allergies, antihistamines relieve stuffiness treat CF patients include Winston Vaughn, Director
Load more

Recommended publications
  • Rhinotillexomania in a Cystic Fibrosis Patient Resulting in Septal Perforation Mark Gelpi1*, Emily N Ahadizadeh1,2, Brian D’Anzaa1 and Kenneth Rodriguez1
    ISSN: 2572-4193 Gelpi et al. J Otolaryngol Rhinol 2018, 4:036 DOI: 10.23937/2572-4193.1510036 Volume 4 | Issue 1 Journal of Open Access Otolaryngology and Rhinology CASE REPORT Rhinotillexomania in a Cystic Fibrosis Patient Resulting in Septal Perforation Mark Gelpi1*, Emily N Ahadizadeh1,2, Brian D’Anzaa1 and Kenneth Rodriguez1 1 Check for University Hospitals Cleveland Medical Center, USA updates 2Case Western Reserve University School of Medicine, USA *Corresponding author: Mark Gelpi, MD, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA, Tel: (216)-844-8433, Fax: (216)-201-4479, E-mail: [email protected] paranasal sinuses [1,4]. Nasal symptoms in CF patients Abstract occur early, manifesting between 5-14 years of age, and Cystic fibrosis (CF) is a multisystem disease that can have represent a life-long problem in this population [5]. Pa- significant sinonasal manifestations. Viscous secretions are one of several factors in CF that result in chronic sinona- tients with CF can develop thick nasal secretions con- sal pathology, such as sinusitis, polyposis, congestion, and tributing to chronic rhinosinusitis (CRS), nasal conges- obstructive crusting. Persistent discomfort and nasal man- tion, nasal polyposis, headaches, and hyposmia [6-8]. ifestations of this disease significantly affect quality of life. Sinonasal symptoms of CF are managed medically with Digital manipulation and removal of crusting by the patient in an attempt to alleviate the discomfort can have unfore- topical agents and antibiotics, however surgery can be seen damaging consequences. We present one such case warranted due to the chronic and refractory nature of and investigate other cases of septal damage secondary to the symptoms, with 20-25% of CF patients undergoing digital trauma, as well as discuss the importance of sinona- sinus surgery in their lifetime [8].
    [Show full text]
  • Cryptogenic Organizing Pneumonia—Results of Treatment with Clarithromycin Versus Corticosteroids—Observational Study
    RESEARCH ARTICLE Cryptogenic organizing pneumoniaÐResults of treatment with clarithromycin versus corticosteroidsÐObservational study Elżbieta Radzikowska1*, Elżbieta Wiatr1☯, Renata Langfort2³, Iwona Bestry3³, Agnieszka Skoczylas4, Ewa Szczepulska-Wo jcik2³, Dariusz Gawryluk1☯, Piotr Rudziński5³, Joanna Chorostowska-Wynimko6³, Kazimierz Roszkowski-Śliż1³ 1 III Department of Lung Disease National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland, 2 Pathology Department National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland, 3 Radiology Department National Tuberculosis and Lung Diseases Research Institute, Warsaw, a1111111111 Poland, 4 Geriatrics Department National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, a1111111111 Poland, 5 Thoracic Surgery Department National Tuberculosis and Lung Diseases Research Institute, a1111111111 Warsaw, Poland, 6 Laboratory of Molecular Diagnostics and Immunology National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland a1111111111 a1111111111 ☯ These authors contributed equally to this work. ³ These authors also contributed equally to this work. * [email protected] OPEN ACCESS Abstract Citation: Radzikowska E, Wiatr E, Langfort R, Bestry I, Skoczylas A, Szczepulska-WoÂjcik E, et al. (2017) Cryptogenic organizing pneumoniaÐ Background Results of treatment with clarithromycin versus Cryptogenic organizing pneumonia (COP) is a clinicopathological syndrome of unknown ori- corticosteroidsÐObservational study. PLoS ONE 12(9): e0184739.
    [Show full text]
  • Does Cystic Fibrosis Constitute an Advantage in COVID-19 Infection? Valentino Bezzerri, Francesca Lucca, Sonia Volpi and Marco Cipolli*
    Bezzerri et al. Italian Journal of Pediatrics (2020) 46:143 https://doi.org/10.1186/s13052-020-00909-1 LETTER TO THE EDITOR Open Access Does cystic fibrosis constitute an advantage in COVID-19 infection? Valentino Bezzerri, Francesca Lucca, Sonia Volpi and Marco Cipolli* Abstract The Veneto region is one of the most affected Italian regions by COVID-19. Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), may constitute a risk factor in COVID-19. Moreover, respiratory viruses were generally associated with severe pulmonary impairment in cystic fibrosis (CF). We would have therefore expected numerous cases of severe COVID-19 among the CF population. Surprisingly, we found that CF patients were significantly protected against infection by SARS-CoV-2. We discussed this aspect formulating some reasonable theories. Keywords: Cystic fibrosis, SARS-CoV-2, Covid-19, Azythromycin, DNase Introduction status, one would surmise that CF patients would be at The comorbidities of obesity, hypertension, diabetes, an increased risk of developing severe COVID-19 illness. heart failure, and chronic lung disease have been associ- ated with poor outcome in coronavirus disease 2019 Methods (COVID-19) [1]. Once Severe Acute Respiratory Syn- We conducted a retrospective study of 532 CF patients – drome (SARS) Coronavirus (CoV)-2 has infected host followed at the Cystic Fibrosis Center of Verona, Italy. cells, excessive inflammatory and thrombotic processes SARS-CoV-2 positivity was tested by collecting com- take place. A cytokine storm release with markedly ele- bined nose-throat swabs and subsequent Real-Time PCR vated IL-6 levels are associated with increased lethality using the Nimbus MuDT tm (Seegene, Seoul, South [2].
    [Show full text]
  • Bronchodilator Responsiveness in Children with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
    AGORA | RESEARCH LETTER Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis Mordechai Pollak 1, Michelle Shaw2, David Wilson1, Hartmut Grasemann1,2 and Felix Ratjen1,2 Affiliations: 1Division of Respiratory Medicine, Hospital for Sick Children, Toronto, ON, Canada. 2Translational Medicine, Sickkids Research Institute, Toronto, ON, Canada. Correspondence: Mordechai Pollak, Hospital for Sick Children, SickKids Learning Institute, Respiratory Medicine, 555 University Ave, Toronto, ON M5G 1X8, Canada. E-mail: [email protected] @ERSpublications CF patients with a new diagnosis of ABPA had a similar BD response, compared to CF patients with acute lung function deterioration from other causes. BD response testing did not help differentiating ABPA from other causes of lung function deterioration. https://bit.ly/39Oegnh Cite this article as: Pollak M, Shaw M, Wilson D, et al. Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis. Eur Respir J 2020; 56: 2000175 [https://doi.org/ 10.1183/13993003.00175-2020]. This single-page version can be shared freely online. To the Editor: Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease that occurs in approximately 9% of children with cystic fibrosis (CF) [1]. While ABPA is commonly associated with worsening lung function, differentiating ABPA from other causes of pulmonary function decline often poses a clinical challenge. This is reflected by major differences among the various diagnostic criteria for ABPA that have been suggested to date [2–5]. A positive bronchodilator response (BDR) is characteristic for asthma which is a common co-morbidity in CF patients, but whether this is helpful in differentiating ABPA from other causes of deterioration in lung function is currently unclear.
    [Show full text]
  • Infection Control Recommendations for Patients with Cystic Fibrosis
    S6 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY May 2003 INFECTION CONTROL RECOMMENDATIONS FOR PATIENTS WITH CYSTIC FIBROSIS: MICROBIOLOGY, IMPORTANT PATHOGENS, AND INFECTION CONTROL PRACTICES TO PREVENT PATIENT-TO-PATIENT TRANSMISSION Lisa Saiman, MD, MPH; Jane Siegel, MD; and the Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants EXECUTIVE SUMMARY (d) The previously published HICPAC/CDC guidelines for Infection Control Recommendations for Patients With prevention of healthcare-associated infections have not Cystic Fibrosis: Microbiology, Important Pathogens, and included background information and recommenda- Infection Control Practices to Prevent Patient-to-Patient tions for the specific circumstances of patients with CF. Transmission updates, expands, and replaces the con- Thus, specific guidelines for CF patients are needed. sensus statement, Microbiology and Infectious Disease in (e) The link between acquisition of pathogens and morbidity Cystic Fibrosis published in 1994.1 This consensus docu- and mortality is well established. Prevention of acquisi- ment presents background data and evidence-based rec- tion of specific pathogens may further improve the mean ommendations for practices that are intended to decrease survival of CF patients, which has increased to 33.4 years the risk of transmission of respiratory pathogens among in 2001.3-9 CF patients from contaminated respiratory therapy equip- A multidisciplinary committee consisting of health- ment or the contaminated environment and thereby reduce care professionals from the United States, Canada, and the burden of respiratory illness. Included are recommen- Europe with experience in CF care and healthcare epi- dations applicable in the acute care hospital, ambulatory, demiology/infection control reviewed the relevant litera- home care, and selected non-healthcare settings.
    [Show full text]
  • The Cystic Fibrosis Foundation Leading the Way
    The Cystic Fibrosis Foundation Leading the Way Cystic fibrosis is a rare, genetic disease that progressively limits the ability to breathe. To combat this condition, the Cystic Fibrosis Foundation was founded in 1955 by parents desperate to save their children’s lives. Their impassioned determination to prolong life has resulted in tremendous strides over the past 60 years in accelerating research and drug development. About cystic fibrosis Median predicted age is into the Americans are symptomless carriers Americans have CF. of the defective CF gene. Living with CF is a struggle The defective CF Some with CF gene causes a thick say it feels buildup of like they are mucus in breathing the lungs through and the a straw. hours a day are spent pancreas. doing treatments. (That’s 1 month a year.) A long, costly road to a cure promising therapies are was spent by the CF Foundation on cures exist currently in development. its mission and advancing new for cystic fibrosis. therapies over the past 25 years. We will not rest until we have a cure for those living with cystic fibrosis. The CF Foundation is a proven leader in the field of rare disease research and is recognized globally for its unprecedented advancements. The Foundation will continue to invest heavily in science supporting its mission so that we can add tomorrows to the lives of those with this disease – and help improve quality of life today. As of September 2018 Jordan, age 22 While people with CF are living longer than in the past, we still lose precious young lives every day.
    [Show full text]
  • Article First Wave of COVID-19 in French Patients with Cystic Fibrosis
    Supplementary material First Wave of COVID-19 in French Patients with Cystic Fibrosis Harriet Corvol 1,2,*, Sandra de Miranda 3, Lydie Lemonnier 4, Astrid Kemgang 2, Martine Reynaud Gaubert 5,6, Raphael Chiron 7, Marie-Laure Dalphin 8, Isabelle Durieu 9, Jean-Christophe Dubus 10, Véronique Houdouin 11, Anne Prevotat 12, Sophie Ramel 13, Marine Revillion 14, Laurence Weiss 15, Loic Guillot 2, Pierre-Yves Boelle 16 and Pierre-Régis Burgel 17,18 on behalf the French Cystic Fibrosis Reference Network study group Supplementay material Expected Number and Age Distribution of COVID-19 in French Patients with Cystic Fibrosis We obtained the cumulated number of hospitalized COVID-19 cases in the French general population up to 30 June 2020. These data are open source, available from data.gouv.fr (https://www.data.gouv.fr/fr/datasets/r/41b9bd2a-b5b6-4271-8878-e45a8902ef00). Then, we obtained the probability of hospitalization upon SARS-Cov-2 infection by age from Table S1 in Salje et al. [21]. The numbers of people in each age class in France were obtained from census data (https://www.insee.fr/fr/statistiques/1892086?sommaire=1912926). From these data, we computed the extrapolated percentage of infections by age class up to 30 June 2020 in the general French population using proportionality rules. Finally, we computed the expected number of infections that would have been expected in the French CF population had the risk of infection been the same as in the general population. We used the number of CF patients from the national registry as the denominator to compute the expected number of SARS-Cov-2 CF cases [1].
    [Show full text]
  • Clinical Guidance on COVID- 19 Vaccines for People with Cystic Fibrosis
    Clinical Guidance on COVID- 19 Vaccines for People with Cystic Fibrosis This guidance is intended for health-care providers. It is based on known evidence as of June 16, 2020. Background and Context The SARS-CoV-2 pandemic has been of particular concern for the cystic fibrosis (CF) community. CF is a multisystem condition with comorbidities that are expected to increase vulnerability to COVID-19. This guidance is based on a review of three of the vaccines approved by Health Canada for the prevention of COVID-19 disease caused by the SARS-CoV-2 virus: Pfizer-BioNTech (BNT162b2)1 and Moderna (mRNA-1273)2, both of which are mRNA vaccines, as well as AstraZeneca/COVISHIELD (ChADOx1-S)3 which is a replication defective adenoviral vector (‘viral vector’) vaccine. Currently, anyone aged 12+ (born in 2009 and later) in British Columbia is eligible for COVID-19 immunization. At this time, only the Pfizer-BioNTech mRNA vaccine is authorized for youth aged 12 and above,3 and we are expecting that Health Canada will authorize the Moderna mRNA vaccine for 12-17 year olds in the near future. Studies of the COVID-19 vaccines in younger children are ongoing. As per the National Advisory Committee on Immunization (NACI)4, the two mRNA vaccines authorized in Canada (Pfizer- BioNTech and Moderna) can be interchanged for the second dose to complete the series, if the vaccine received for the first dose is not available or is unknown. No data currently exist on the interchangeability of the COVID-19 mRNA vaccines. However, there is no reason to believe that mRNA vaccine series completion with a different authorized mRNA vaccine product will result in any additional safety issues of deficiency in protection.
    [Show full text]
  • COVID-19 & Cystic Fibrosis
    COVID-19 & Cystic Fibrosis People with cystic fibrosis (CF) may have anxiety about their health during the COVID-19 pandemic. However, there isn’t any evidence to suggest that those with CF are more likely to contract COVID-19 according to Dr. Jennifer Taylor-Cousar, co-director of the Adult Cystic Fibrosis Program at National Jewish Health. “What we do know is that those with CF are more at risk to have severe effects of COVID-19 on their lungs.” Cystic fibrosis patients are used to social distancing and taking extra precautions to keep from getting sick. In fact, these habits may be the reason that fewer than expected cystic fibrosis patients have reported contracting COVID-19. Dr. Taylor-Cousar says, “Overall, people with CF aren’t catching COVID-19 frequently, most likely because they are used to washing their hands frequently, staying home and staying six feet away from other people.” Routine Care for Cystic Fibrosis during COVID-19 The COVID-19 pandemic has made getting treatment for cystic fibrosis at health care centers harder. The Cystic Fibrosis Foundation recommends that patients see their doctors quarterly for an in depth checkup. During the pandemic, according to Dr. Taylor-Cousar, many health care providers are using telehealth to connect with CF patients. “Telehealth let’s doctors give patients advice about their medications, and anything that needs to change because of mild COVID symptoms without the patient having to leave their house,” she explained. COVID-19 Treatment for CF Patients If a cystic fibrosis patient does become sick with COVID-19, the patient’s treatment may look the same as a patient without CF.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis in a Patient with Chronic Obstructive Pulmonary Disease
    Prim Care Respir J 2012; 21(1): 111-114 CASE-BASED LEARNING Allergic bronchopulmonary aspergillosis in a patient with chronic obstructive pulmonary disease Elias Mira,*Ashok Shaha a Department of Respiratory Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India Originally received 13th April 2011; resubmitted 27th July 2011; revised 16th September 2011; accepted 17th September 2011; online 5th January 2012 Summary Allergic bronchopulmonary aspergillosis (ABPA) is a debilitating lung disease which occurs as a result of interplay between a variety of host and environmental factors. It occurs in certain susceptible individuals who develop hypersensensitivity to the colonised Aspergillus species. ABPA is a complicating factor in 2% of patients with asthma and is also seen in patients with cystic fibrosis. Asthma and chronic obstructive pulmonary disease (COPD) are known to share key elements of pathogenesis. It is well known that ABPA can occur in patients with asthma, but it has recently been reported in patients with COPD as well. We report a 55-year-old male ex-smoker who presented with complaints of exertional breathlessness and productive cough for five years and an episode of haemoptysis four days prior to presentation. Spirometery showed airflow obstruction which was not reversible with bronchodilators. Chest CT scan revealed paraseptal emphysema along with central bronchiectasis (CB) in the right upper lobe and bilateral lower lobes. A type I skin hypersensitivity reaction to Aspergillus species was elicited. He fulfilled the serological criteria for ABPA and was diagnosed as having concomitant COPD and ABPA-CB. The patient was initiated on therapy for COPD along with oral corticosteroids, on which he had remarkable symptomatic improvement.
    [Show full text]
  • Cryptogenic Organizing Pneumonia
    462 Cryptogenic Organizing Pneumonia Vincent Cottin, M.D., Ph.D. 1 Jean-François Cordier, M.D. 1 1 Hospices Civils de Lyon, Louis Pradel Hospital, National Reference Address for correspondence and reprint requests Vincent Cottin, Centre for Rare Pulmonary Diseases, Competence Centre for M.D., Ph.D., Hôpital Louis Pradel, 28 avenue Doyen Lépine, F-69677 Pulmonary Hypertension, Department of Respiratory Medicine, Lyon Cedex, France (e-mail: [email protected]). University Claude Bernard Lyon I, University of Lyon, Lyon, France Semin Respir Crit Care Med 2012;33:462–475. Abstract Organizing pneumonia (OP) is a pathological pattern defined by the characteristic presence of buds of granulation tissue within the lumen of distal pulmonary airspaces consisting of fibroblasts and myofibroblasts intermixed with loose connective matrix. This pattern is the hallmark of a clinical pathological entity, namely cryptogenic organizing pneumonia (COP) when no cause or etiologic context is found. The process of intraalveolar organization results from a sequence of alveolar injury, alveolar deposition of fibrin, and colonization of fibrin with proliferating fibroblasts. A tremen- dous challenge for research is represented by the analysis of features that differentiate the reversible process of OP from that of fibroblastic foci driving irreversible fibrosis in usual interstitial pneumonia because they may determine the different outcomes of COP and idiopathic pulmonary fibrosis (IPF), respectively. Three main imaging patterns of COP have been described: (1) multiple patchy alveolar opacities (typical pattern), (2) solitary focal nodule or mass (focal pattern), and (3) diffuse infiltrative opacities, although several other uncommon patterns have been reported, especially the reversed halo sign (atoll sign).
    [Show full text]
  • Cystic Fibrosis
    cf_new3.qxd 2/21/96 3:14 PM Page 1 FACTS ABOUT Cystic Fibrosis What Is Cystic Fibrosis What Are the Signs and Symptoms Cystic fibrosis (CF) is a chronic, progressive, of CF? and frequently fatal genetic (inherited) dis­ CF does not follow the same pattern in all ease of the body’s mucus glands. CF pri­ patients but affects different people in dif­ marily affects the respiratory and digestive ferent ways and to varying degrees. systems in children and young adults. The However, the basic problem is the same— sweat glands and the reproductive system an abnormality in the glands, which pro­ are also usually involved. On the average, duce or secrete sweat and mucus. Sweat individuals with CF have a lifespan of cools the body; mucus lubricates the respi­ approximately 30 years. ratory, digestive, and reproductive systems, and prevents tissues from drying out, pro­ CF-like disease has been known for over tecting them from infection. two centuries. The name, cystic fibrosis of the pancreas, was first applied to the disease People with CF lose excessive amounts of in 1938. salt when they sweat. This can upset the balance of minerals in the blood, which may How Common Is CF? cause abnormal heart rhythms. Going into shock is also a risk. According to the data collected by the Cystic Fibrosis Foundation, there are about Mucus in CF patients is very thick and 30,000 Americans, 3,000 Canadians, and accumulates in the intestines and lungs. 20,000 Europeans with CF. The disease The result is malnutrition, poor growth, occurs mostly in whites whose ancestors frequent respiratory infections, breathing came from northern Europe, although it difficulties, and eventually permanent lung affects all races and ethnic groups.
    [Show full text]